Pathogenesis and treatment of Kawasaki's disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Opinion in Rheumatology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.bor.0000174184.15901.eePMID 16093842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endothelial Function Evaluated by Flow-Mediated Dilatation in Pediatric Vascular Disease

  2005cited by this paper
• Association between a Novel Human Coronavirus and Kawasaki Disease

  2005cited by this paper
• The etiology of Kawasaki disease: a superantigen-mediated process

  2004cited by this paper
• Polymorphism of Angiotensin-1 Converting Enzyme Gene and Kawasaki Disease

  2004cited by this paper
• Presence of IFN-γ Does Not Indicate Its Necessity for Induction of Coronary Arteritis in an Animal Model of Kawasaki Disease1

  2004cited by this paper
• Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease

  2004cited by this paper
• Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody.

  2004cited by this paper
• Modulating Effects of Mannose Binding Lectin Genotype on Arterial Stiffness in Children After Kawasaki Disease

  2004cited by this paper
• Possible Synergic Effect of Angiotensin-I Converting Enzyme Gene Insertion/Deletion Polymorphism and Angiotensin-II Type-1 Receptor 1166A/C Gene Polymorphism on Ischemic Heart Disease in Patients with Kawasaki Disease

  2004cited by this paper
• Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease.

  2004cited by this paper
• Treatment of Acute Kawasaki Disease: Aspirin’s Role in the Febrile Stage Revisited

  2004cited by this paper
• Cell Adhesion Molecule Expression in Coronary Artery Aneurysms in Acute Kawasaki Disease

  2004cited by this paper
• Cardiovascular complications—coronary artery structure and function

  2004cited by this paper
• Enhanced iNOS Expression in Leukocytes and Circulating Endothelial Cells Is Associated with the Progression of Coronary Artery Lesions in Acute Kawasaki Disease

  2004cited by this paper
• Infliximab as a novel therapy for refractory Kawasaki disease.

  2004cited by this paper
• Acute management of Kawasaki disease

  2004cited by this paper
• Association of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Gene Polymorphisms with Coronary Artery Lesions of Kawasaki Disease

  2004cited by this paper
• The etiology of Kawasaki Disease: a conventional infectious agent

  2004cited by this paper
• Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.

  2004cited by this paper
• CD25+CD4+ regulatory T cells in patients with Kawasaki disease.

  2004cited by this paper
• Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease.

  2003cited by this paper
• S100A12 (EN-RAGE) in monitoring Kawasaki disease.

  2003cited by this paper
• Systemic Arterial Expression of Matrix Metalloproteinases 2 and 9 in Acute Kawasaki Disease

  2003cited by this paper
• Prognostic Impact of Vascular Leakage in Acute Kawasaki Disease

  2003cited by this paper
• Association between levels of TNF-alpha and TNF-alpha promoter -308 A/A polymorphism in children with Kawasaki disease.

  2003cited by this paper
• A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.

  2003cited by this paper
• Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary arterial lesions

  2003cited by this paper
• Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease.

  2003cited by this paper
• Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.

  2003cited by this paper
• Possible relationship between streptococcal pyrogenic exotoxin A and Kawasaki syndrome in patients older than six months of age

  2003cited by this paper
• Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

  2003cited by this paper
• Plasminogen Activator Inhibitor-1 in Patients with Kawasaki Disease: Diagnostic Value for the Prediction of Coronary Artery Lesion and Implication for a New Mode of Therapy

  2003cited by this paper
• Relation of Streptococcal Pyrogenic Exotoxin C as a Causative Superantigen for Kawasaki Disease

  2003cited by this paper
• Decreased Levels of Cystatin C, an Inhibitor of the Elastolytic Enzyme Cysteine Protease, in Acute and Subacute Phases of Kawasaki Disease

  2003cited by this paper
• Elevated Levels of Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 during the Acute Phase of Kawasaki Disease

  2003cited by this paper
• Evaluation of the Efficacy of Treatment of Kawasaki Disease before Day 5 of Illness

  2003cited by this paper
• Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea.

  2003cited by this paper
• Inducible and endothelial constitutive nitric oxide synthase gene polymorphisms in Kawasaki disease

  2003cited by this paper
• Serial changes of plasma nitrate in the acute phase of Kawasaki disease

  2003cited by this paper
• Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10.

  2003cited by this paper
• Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.

  2003cited by this paper
• ASSOCIATION BETWEEN LEVELS OF TNF-α AND TNF-α PROMOTER -308 A/A POLYMORPHISM IN CHILDREN WITH KAWASAKI DISEASE

  2003cited by this paper
• Early Treatment with Intravenous Immunoglobulin in Patients with Kawasaki Disease

  2002cited by this paper
• Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome.

  2002cited by this paper
• Oligoclonal IgA Response in the Vascular Wall in Acute Kawasaki Disease1

  2001cited by this paper
• Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression.

  2000cited by this paper
• Cyclooxygenase‐independent inhibition of dendritic cell maturation by aspirin

  2000cited by this paper
• Ultrastructural characteristics of myocardial and coronary microvascular lesions in Kawasaki disease.

  1999cited by this paper
• Decreased interferon-gamma (IFN-gamma)-producing T cells in patients with acute Kawasaki disease.

  1999cited by this paper
• Corticosteroids in the treatment of the acute phase of Kawasaki disease.

  1999cited by this paper
• Decreased interferon‐gamma (IFN‐γ)‐producing T cells in patients with acute Kawasaki disease

  1999cited by this paper
• Coronary artery dimensions may be misclassified as normal in Kawasaki disease.

  1998cited by this paper
• Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats.

  1997cited by this paper
• Impaired endothelial function in epicardial coronary arteries after Kawasaki disease.

  1997cited by this paper
• Endothelial dysfunction late after Kawasaki disease.

  1996cited by this paper
• The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.

  1995cited by this paper
• Inhibition of NF-kappa B by sodium salicylate and aspirin.

  1994cited by this paper
• Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

  1994cited by this paper
• Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.

  1993cited by this paper
• A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

  1991cited by this paper
• Nationwide survey of Kawasaki disease and acute rheumatic fever.

  1991cited by this paper
• The treatment of Kawasaki syndrome with intravenous gamma globulin.

  1986cited by this paper
• The treatment of Kawasaki syndrome with intravenous gamma globulin.

  1986cited by this paper
• Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension.

  1985cited by this paper
• Kawasaki disease: effect of treatment on coronary artery involvement.

  1979cited by this paper
• A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan.

  1974cited by this paper
• [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

  1967cited by this paper

• Evaluating the quality and reliability of Kawasaki disease–related content on TikTok and Bilibili: a cross-sectional study

  2026cites this paper
• SUSPECT KAWASAKI DISEASE PADA ANAK LAKI – LAKI BALITA PADA RUMAH SAKIT SUMBER WARAS JAKARTA BARAT

  2025cites this paper
• An update on understanding the pathophysiology in Kawasaki disease: Possible role of immune complexes in coronary artery lesion revisited

  2023cites this paper
• The Role of Circulating Immune Complexes in Coronary Artery Lesions: Understanding possible Patho-Physiology in Kawasaki Disease Revisited

  2022cites this paper
• Identifying differentially expressed genes and miRNAs in Kawasaki disease by bioinformatics analysis

  2022cites this paper
• Ocular Manifestations of Systemic Vasculitides

  2021cites this paper
• Kawasaki-like disease in children with COVID-19: A hypothesis

  2020cites this paper
• Kawasaki disease with a concomitant primary Epstein - Barr virus infection

  2020cites this paper
• Inflammatory and Purpuric Eruptions

  2020cites this paper
• KAWASAKİ HASTALIĞI VE DENTAL YAKLAŞIMLAR

  2020cites this paper
• Facial nerve palsy presenting as rare neurological complication of Kawasaki disease

  2019influential citation
• Causes of Kawasaki Disease—From Past to Present

  2019cites this paper
• [Kawasaki disease].

  2019cites this paper
• The Role of T-cell Costimulation in the Pathogenesis of Kawasaki Disease

  2019cites this paper
• Facial Nerve Palsy and Kawasaki Disease

  2014cites this paper
• Kawasaki Disease-Specific Molecules in the Sera Are Linked to Microbe-Associated Molecular Patterns in the Biofilms

  2014cites this paper
• The Role of TLR2 in the Pathogenesis of Kawasaki Disease

  2012cites this paper
• The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease

  2011cites this paper
• A regulatory polymorphism in promoter region of TNFR1 gene is associated with Kawasaki disease in Chinese individuals.

  2011cites this paper
• Increased frequency of immunoglobulin (Ig)A‐secreting cells following Toll‐like receptor (TLR)‐9 engagement in patients with Kawasaki disease

  2011cites this paper
• Advanced Non-invasive Imaging in Assessment of Kawasaki's Disease: Low-Dose Computed Tomography and Magnetic Resonance Imaging

  2011cites this paper
• Erupciones inflamatorias y purpúricas

  2010cites this paper
• Kawasaki Disease in Two Cousins with Atypical Presentation: Case Report

  2010cites this paper
• Translational Concepts in Vasculitis

  2010cites this paper
• CHAPTER 13 – Rheumatic Diseases of Childhood: Therapeutic Principles

  2010cites this paper
• Licensed Vaccines for Rotavirus Prevention in the US: A Review

  2009cites this paper
• Miscellaneous Disorders With Prominent Features Involving the Skin and the Joints

  2009cites this paper
• Klonierung und molekulare Charakterisierung humaner, monoklonaler Antikörper einer Patientin mit Kawasaki-Syndrom vor und nach Behandlung mit IVIG mittels kombinatorischer Phagen-Display-Bibliothek

  2009cites this paper
• Long-term follow-up of acute changes in coronary artery diameter caused by Kawasaki disease: risk factors for development of stenotic lesions

  2009cites this paper
• Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease

  2009cites this paper
• Bilateral facial nerve palsy in Kawasaki disease.

  2009cites this paper
• Doença de Kawasaki

  2009cites this paper
• Pathogenesis of Kawasaki disease: the central role of TNF-α

  2008cites this paper
• Ocular Manifestations of Systemic Vasculitides

  2008cites this paper
• Adverse events following immunization: perception and evidence

  2007cites this paper
• Clinical factors causing hyperbilirubinemia in patients with Kawasaki disease

  2007cites this paper
• Kawasaki Disease: Four Case Reports of Cardiopathy with an Institutional and Literature Review

  2007cites this paper
• The role of superantigens of group A Streptococcus and Staphylococcus aureus in Kawasaki disease

  2007cites this paper
• Kawasaki Syndrome in Denmark

  2007cites this paper
• Skin Signs of Systemic Disease in Childhood

  2006cites this paper
• A child with a systemic febrile illness - differential diagnosis and management.

  2006cites this paper
• Kawasaki disease onset during concomitant infections with varicella zoster and Epstein-Barr virus.

  2006cites this paper
• Models of Kawasaki disease

  2006cites this paper
• Table 1 Selected Laboratory Tests for Patients with Multisystem Disease and Possible Vasculitis

  2003cites this paper